Functional Dyspepsia Pipeline, Clinical Trials, and Emerging Drugs (2023) | Companies – Renexxion, Daewoong Pharmaceutical, RaQualia Pharmaceutical, and Others
DelveInsight’s, “Functional Dyspepsia Pipeline Insight 2023” report provides comprehensive insights about 4+ companies and 4+ pipeline drugs in the Functional Dyspepsia pipeline landscape. It covers the Functional Dyspepsia pipeline drug profiles, including Functional Dyspepsia clinical trials and nonclinical stage products. It also covers the Functional Dyspepsia therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.
For the Functional Dyspepsia emerging drugs, the pipeline analysis report presents a comprehensive view of the therapeutic landscape, considering the development stage, product type, route of administration, molecule type, and mechanism of action (MOA). The research on the Functional Dyspepsia pipeline covers various aspects such as business opportunities, challenges, potential partnerships, strong competitors, and growth strategies. It provides a detailed description of each drug, including its mechanism of action, Functional Dyspepsia clinical trial studies conducted for Functional Dyspepsia, any NDA approvals obtained for Functional Dyspepsia, and the product development activities encompassing technology, collaborations, licensing, mergers and acquisitions, funding, designations, and other relevant details.
To explore more information on the latest breakthroughs in the Functional Dyspepsia Pipeline treatment landscape of the report, click here @ Functional Dyspepsia Pipeline Outlook
Key Takeaways from the Functional Dyspepsia Pipeline Report
- DelveInsight’s Functional Dyspepsia Pipeline analysis depicts a robust space with 4+ active players working to develop 4+ pipeline treatment therapies.
- The leading Functional Dyspepsia Companies are working in the market include Renexxion, Daewoong Pharmaceutical, RaQualia Pharmaceutical, Zeria Pharmaceutical, Korea United Pharm Inc, Daewoong Pharmaceutical Co. Ltd, Johnsons & Johnsons, Eisai Co, GlaxoSmithKline, and others
- Promising Functional Dyspepsia Pipeline Therapies in the various stages of development include GW679769 oral tablets, Z-338, Rabeprazole, Espumisan, Imonogas, Gasmotin, DWJ1252, UI05MSP015CT, Acotiamide hydrochloride hydrate, DLBS2411, and others
- Renexxion’s Naronapride is in the phase II stage of the drug development process. The drug candidate is an orally administered small organic molecule. It was designed to be an effective and selective serotonin 5-HT4 receptor agonist. This works by stimulating the activity of 5-HT4 receptors present in the wall of gut which promotes the release of acetylcholine, thereby increasing the motility of the GI tract.
- Daewoong Pharmaceutical’s DWJ 1252 is reported to be in the Phase III of the drug development. It belongs to the class of small molecules and follows the mechanism of action of serotonin 4 receptor agonists. It is also known as mosapride sustained release formulation.
Functional Dyspepsia Overview
Functional dyspepsia is a term assigned for referring to recurring signs and symptoms associated with indigestion with no obvious cause. It is also referred to as nonulcer dyspepsia or nonulcer stomach pain. Presently, there is no treatment available for treating functional dyspepsia completely. The condition can be managed by medication, changing lifestyle habits, and a combination of the two. Medications include pan medication, treating helicobacter pylori treatment, and medication aimed at reducing the acid in the stomach.
For further information, refer to the detailed Functional Dyspepsia Unmet Needs, Functional Dyspepsia Market Drivers, and Market Barriers, click here for Functional Dyspepsia Ongoing Clinical Trial Analysis
Functional Dyspepsia Emerging Drugs Profile
- Naronapride: Renexxion
- DWJ 1252: Daewoong Pharmaceutical
Functional Dyspepsia Pipeline Therapeutics Assessment
There are approx. 4+ Functional Dyspepsia companies which are developing the therapies for Functional Dyspepsia. The Functional Dyspepsia companies which have their Functional Dyspepsia drug candidates in the mid to advanced stage, i.e. phase III and Phase II include, Renexxion and others.
Request a sample and discover the recent advances in Functional Dyspepsia Ongoing Clinical Trial Analysis and Medications, click here @ Functional Dyspepsia Treatment Landscape
Functional Dyspepsia Therapeutics Assessment
- Assessment by Stage and Product Type
- Assessment by Route of Administration
- Assessment by Stage and Route of Administration
- Assessment by Molecule Type
- Assessment by Stage and Molecule Type
Some of the Companies in the Functional Dyspepsia Therapeutics Market include-
Renexxion, Daewoong Pharmaceutical, RaQualia Pharmaceutical, Zeria Pharmaceutical, Korea United Pharm Inc, Johnsons & Johnsons, Eisai Co, GlaxoSmithKline, and others.
Scope of the Functional Dyspepsia Pipeline Report
- Coverage- Global
- Functional Dyspepsia Companies- Renexxion, Daewoong Pharmaceutical, RaQualia Pharmaceutical, Zeria Pharmaceutical, Korea United Pharm Inc, Johnsons & Johnsons, Eisai Co, GlaxoSmithKline, and others.
- Functional Dyspepsia Therapies- GW679769 oral tablets, Z-338, Rabeprazole, Espumisan, Imonogas, Gasmotin, DWJ1252, UI05MSP015CT, Acotiamide hydrochloride hydrate, DLBS2411, and others
- Functional Dyspepsia Segmentation- Product Type, Molecule Type, Route of Administration
Got Queries? Find out the related information on Functional Dyspepsia Mergers and acquisitions, Functional Dyspepsia Licensing Activities @ Functional Dyspepsia Emerging Drugs, and Recent Trends
Table of Content
- Introduction
- Functional Dyspepsia Executive Summary
- Functional Dyspepsia: Overview
- Functional Dyspepsia Pipeline Therapeutics
- Functional Dyspepsia Therapeutic Assessment
- Functional Dyspepsia – DelveInsight’s Analytical Perspective
- In-depth Commercial Assessment
- Functional Dyspepsia Collaboration Deals
- Late Stage Products (Phase III)
- DWJ 1252: Daewoong Pharmaceuticals
- Drug profiles in the detailed report…..
- Mid Stage Products (Phase II)
- Naronapride: Renexxion
- Drug profiles in the detailed report…..
- Pre-clinical and Discovery Stage Products
- Drug profiles in the detailed report…..
- Inactive Products
- Functional Dyspepsia Key Companies
- Functional Dyspepsia Key Products
- Functional Dyspepsia- Unmet Needs
- Functional Dyspepsia- Market Drivers and Barriers
- Functional Dyspepsia- Future Perspectives and Conclusion
- Functional Dyspepsia Analyst Views
- Functional Dyspepsia Key Companies
- Appendix
About Us
DelveInsight is a Business Consulting and Market research company, providing expert business solutions for the healthcare domain and offering quintessential advisory services in the areas of R&D, Strategy Formulation, Operations, Competitive Intelligence, Competitive Landscaping, and Mergers & Acquisitions.
Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Yash Bhardwaj
Email: Send Email
Phone: 9193216187
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/case-study/market-&-competitive-assessment
 | Companies – Renexxion, Daewoong Pharmaceutical, RaQualia Pharmaceutical, and Others){kind=link}